Steven BASTA,Paul KWON,Xiaoming ZHANG,Cyrus K. BECKER,Meenakshi S. VENKATRAMAN
申请号：
US15873732
公开号：
US20180235931A1
申请日:
2018.01.17
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The disclosure relates to the use of neurokinin-1 (NK-1) antagonists, such as serlopitant, MK-0303 or MK-8478, in alleviating or suppressing cough (including acute, subacute and chronic cough) and urge to cough. The cough can have an unknown cause (idiopathic cough) or can be associated with any type of medical condition, such as a respiratory disorder. The NK-1 antagonist can be delivered by oral inhalation for more rapid peripheral and central antitussive action. Another antitussive agent in addition to the NK-1 antagonist can optionally be administered for the treatment of the cough or urge to cough, or the cough-associated medical condition.
